Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
DSM says its new biomanufacturing facility will benefit the Australian biotech sector, overcoming the problems of distance with foreign contract manufacturers.
DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
